Search results
Results from the WOW.Com Content Network
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), formerly the National Center for HIV, STD, and TB Prevention (NCHSTP) is a part of the Centers for Disease Control and Prevention and is responsible for public health surveillance, prevention research, and programs to prevent and control human immunodeficiency virus (HIV) infection and acquired ...
The HIV/AIDS Bureau is a part of the Health Resources and Services Administration (HRSA), an agency of the United States Department of Health and Human Services.The HIV/AIDS Bureau was established in 1990 as a part of the Ryan White CARE Act and is most notable for the Ryan White HIV/AIDS Program, which stands as the U.S. government's social response to the HIV/AIDS epidemic of the late 20th ...
In December 2014, PEPFAR announced a program PEPFAR 3.0 focusing on Sustainable Control of the AIDS epidemic. This program was designed to address the UNAIDS "90-90-90" global goal: 90 percent of people with HIV diagnosed, 90 percent of them on ART and 90 percent of them virally suppressed by the year 2020. [12]
In fiscal year 2005, federal funding for the Ryan White CARE Act was $2.1 billion. As of 2005, roughly one-third of this money went to the AIDS Drug Assistance Programs (ADAP) which provides drugs for 30 percent of people living with HIV. [3] The primary activity of ADAP is providing FDA-approved prescription medication. [4]
Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [2] It contains two antiretroviral medications, lamivudine and zidovudine. [2]
Dolutegravir is approved for use in a broad population of HIV-infected patients. It can be used to treat HIV-infected adults who have never taken HIV therapy (treatment-naïve) and HIV-infected adults who have previously taken HIV therapy (treatment-experienced), including those who have been treated with other integrase strand transfer inhibitors.
In spite of Pfizer's list price of US$1,390 for five days in the US, treatment has been and will be free through the end of 2024 for Medicare or Medicaid beneficiaries and insured persons covering out-of-pocket costs. [29] [79] Pfizer reported revenue of US$1.279 billion for Paxlovid in 2023. [80]